Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis

References

• Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.2133826808342
   PubMed Web of Science ®Google Scholar
• Liu C, Chen T, Zeng W, et al. Reevaluating the prognostic significance of male gender for papillary thyroid carcinoma and microcarcinoma: a SEER database analysis. Sci Rep. 2017;7(1):11412. doi:10.1038/s41598-017-11788-828900207
   PubMedGoogle Scholar
• Brito JP, Hay ID, Morris JC. Low risk papillary thyroid cancer. BMJ. 2014;348:g3045. doi:10.1136/bmj.g304524935445
   PubMed Web of Science ®Google Scholar
• Lv T, Zhu C, Di Z. Risk factors stratifying malignancy of nodules in contralateral thyroid lobe in patients with pre-operative ultrasound indicated unilateral papillary thyroid carcinoma: a retrospective analysis from single centre. Clin Endocrinol (Oxf). 2018;88(2):279–284. doi:10.1111/cen.1350629083503
   PubMed Web of Science ®Google Scholar
• Sun T. Long noncoding RNAs act as regulators of autophagy in cancer. Pharmacol Res. 2018;129:151–155. doi:10.1016/j.phrs.2017.11.00929133213
   PubMed Web of Science ®Google Scholar
• Schmitt A, Chang H. Long noncoding RNAs in cancer pathways. Cancer Cell. 2016;29(4):452–463. doi:10.1016/j.ccell.2016.03.01027070700
   PubMed Web of Science ®Google Scholar
• Lee H, Park JE, Nam JM. Bio-barcode gel assay for microRNA. Nat Commun. 2014;5:3367. doi:10.1038/ncomms597224569571
   PubMed Web of Science ®Google Scholar
• Tay Y, Rinn J, Pandolfi PP. The multilayered complexity of ceRNA crosstalk and competition. Nature. 2014;505(7483):344–352. doi:10.1038/nature1298624429633
   PubMed Web of Science ®Google Scholar
• Song B, Li R, Zuo Z, et al. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer. BMC Cancer. 2019;19(1):297. doi:10.1186/s12885-019-5699-930940124
   PubMedGoogle Scholar
• Tang Z, Li C, Kang B, Gao G, Li C, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017;45(W1):W98–W102. doi:10.1093/nar/gkx24728407145
   PubMed Web of Science ®Google Scholar
• Mahmoudian-Sani MR, Jalali A, Jamshidi M, et al. Long non-coding RNAs in thyroid cancer: implications for pathogenesis, diagnosis, and therapy. Oncol Res Treat. 2019;42(3):136–142. doi:10.1159/00049515130799425
   PubMed Web of Science ®Google Scholar
• Goedert L, Plaça JR, Fuziwara CS, et al. Identification of long noncoding RNAs deregulated in papillary thyroid cancer and correlated with BRAF V600E mutation by bioinformatics integrative analysis. Sci Rep. 2017;7(1):1662. doi:10.1038/s41598-017-01957-028490781
   PubMedGoogle Scholar
• Liao T, Qu N, Shi RL, et al. BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer. Oncotarget. 2016;8(1):238–247.
   Google Scholar
• Wang XM, Liu Y, Fan YX, et al. LncRNA PTCSC3 affects drug resistance of anaplastic thyroid cancer through STAT3/INO80 pathway. Cancer Biol Ther. 2018;19(4):1–18. doi:10.1080/15384047.2018.144961029281559
   PubMedGoogle Scholar
• Takashi N, Mitchell JA, Sanz LA, et al. The air noncoding RNA epigenetically silences transcription by targeting G9a to chromatin. Science. 2008;322(5908):1717–1720. doi:10.1126/science.116380218988810
   PubMed Web of Science ®Google Scholar
• Wang Y, Chang W, Chang W, et al. MicroRNA-376c-3p facilitates human hepatocellular carcinoma progression via repressing AT-rich interaction domain 2. J Cancer. 2018;9(22):4187–4196. doi:10.7150/jca.2793930519319
   PubMed Web of Science ®Google Scholar
• Zeljic K, Jovanovic I, Jovanovic J, Magic Z, Stankovic A, Supic G. MicroRNA meta-signature of oral cancer: evidence from a meta-analysis. Ups J Med Sci. 2018;123(1):43–49. doi:10.1080/03009734.2018.143955129482431
   PubMed Web of Science ®Google Scholar
• Nunez Lopez YO, Victoria B, Golusinski P, Golusinski W, Masternak MM. Characteristic miRNA expression signature and random forest survival analysis identify potential cancer-driving miRNAs in a broad range of head and neck squamous cell carcinoma subtypes. Rep Pract Oncol Radiother. 2018;23(1):6–20. doi:10.1016/j.rpor.2017.10.00329187807
   PubMedGoogle Scholar
• Huo D, Clayton WM, Yoshimatsu TF, Chen J, Olopade OI. Identification of a circulating microRNA signature to distinguish recurrence in breast cancer patients. Oncotarget. 2016;7(34):55231–55248. doi:10.18632/oncotarget.1048527409424
   PubMedGoogle Scholar
• Bhavsar SP, Lokke C, Flaegstad T, Einvik C. Hsa-miR-376c-3p targets Cyclin D1 and induces G1-cell cycle arrest in neuroblastoma cells. Oncol Lett. 2018;16(5):6786–6794. doi:10.3892/ol.2018.943130405823
   PubMed Web of Science ®Google Scholar
• Tu L, Zhao E, Zhao W, et al. hsa-miR-376c-3p regulates gastric tumor growth both in vitro and in vivo. Biomed Res Int. 2016;2016:9604257. doi:10.1155/2016/960425727965982
   PubMed Web of Science ®Google Scholar
• Wang K, Jin J, Ma T, Zhai H. MiR-376c-3p regulates the proliferation, invasion, migration, cell cycle and apoptosis of human oral squamous cancer cells by suppressing HOXB7. Biomed Pharmacother. 2017;91:517–525. doi:10.1016/j.biopha.2017.04.05028482289
   PubMed Web of Science ®Google Scholar
• Chang WM, Lin YF, Su CY, et al. Dysregulation of RUNX2/Activin-A axis upon miR-376c downregulation promotes lymph node metastasis in head and neck squamous cell carcinoma. Cancer Res. 2016;76(24):7140–7150. doi:10.1158/0008-5472.CAN-16-118827760788
   PubMed Web of Science ®Google Scholar
• Gu C, Yao J, Sun P. Dynamin 3 suppresses growth and induces apoptosis of hepatocellular carcinoma cells by activating inducible nitric oxide synthase production. Oncol Lett. 2017;13(6):4776–4784. doi:10.3892/ol.2017.605728599479
   PubMed Web of Science ®Google Scholar
• Inokawa Y, Nomoto S, Hishida M, et al. Dynamin 3: a new candidate tumor suppressor gene in hepatocellular carcinoma detected by triple combination array analysis. Onco Targets Ther. 2013;6:1417–1424. doi:10.2147/OTT.S5191324143113
   PubMed Web of Science ®Google Scholar
• Zhang Z, Chen C, Guo W, Zheng S, Sun Z, Geng X. DNM3 attenuates hepatocellular carcinoma growth by activating P53. Med Sci Monit. 2016;22:197–205. doi:10.12659/msm.89654526784388
   PubMed Web of Science ®Google Scholar
• Yang JK, Yang JP, Tong J, et al. Exosomal miR-221 targets DNM3 to induce tumor progression and temozolomide resistance in glioma. J Neurooncol. 2017;131(2):255–265. doi:10.1007/s11060-016-2308-527837435
   PubMed Web of Science ®Google Scholar
• Yang JK, Song J, Huo HR, et al. DNM3, p65 and p53 from exosomes represent potential clinical diagnosis markers for glioblastoma multiforme. Ther Adv Med Oncol. 2017;9(12):741–754. doi:10.1177/175883401773747129449895
   PubMed Web of Science ®Google Scholar